Guilin Sanjin released its 2026 interim report, with net profit attributable to the parent company at 261 million yuan, down 9.12% year on year. Total operating revenue was 969 million yuan, down 2.98% year on year. Net cash inflow from operating activities was 160 million yuan, down 49.62% year on year. The latest gross margin was 76.69%, down 5.58 percentage points from the previous quarter. The latest return on equity was 7.99%, down 1.18 percentage points year on year. Diluted earnings per share were 0.44 yuan, down 10.20% year on year.
Guilin Sanjin Pharmaceutical Co LtdNet profit fell 9.12% and revenue declined 2.98% in interim report.
